CCR5 blockade with maraviroc reduces the incidence of acute GVHD. (A) Cumulative incidence of grade 2-4 acute GVHD in control or maraviroc-treated patients. (B) Cumulative incidence of grade 3-4 acute GVHD. (C) Cumulative incidence of visceral GVHD (gut or liver). (D-F) Cumulative incidence of organ-specific GVHD in the skin (D), gut (E), and liver (F). (G) Total bilirubin levels in control or maraviroc-treated patients up to 100 days after transplant. Each line represents an individual patient. The horizontal red line indicates 3 times upper limit of normal. (H) Forest plot of the indicated clinical parameters comparing control or maraviroc-treated patients. Adjusted hazard ratio (HR) and P values are indicated for each comparison.